This search looks for keywords in all of the website’s content. To find specific documents, select 'Include documents' at the top of the left sidebar and filter by document type. More search tips
Filter by
- Agenda(0)
- Annex to CHMP highlights(0)
- Annual Report(0)
- Application withdrawal assessment report(0)
- Committee meeting report(0)
- COVID-19 vaccine safety update(0)
- Direct healthcare professional communication(0)
- EPAR - All authorised presentations(0)
- EPAR - Amended Product Information(0)
- EPAR - Assessment report - Variation(0)
- EPAR - Assessment report on maintenance of orphan designation - Initial authorisation(0)
- EPAR - Assessment report on maintenance of orphan designation - Post-authorisation(0)
- EPAR - Conditions imposed on member states for safe and effective use(0)
- EPAR - Overview(0)
- EPAR - Paediatric investigation plan compliance statement(0)
- EPAR - Procedural steps taken and scientific information after authorisation(0)
- EPAR - Procedural steps taken before authorisation(0)
- EPAR - Product Information(0)
- EPAR - Public assessment report(0)
- EPAR - Risk-management-plan summary(0)
- EPAR - Risk management plan(0)
- EPAR - Scientific conclusion(0)
- EPAR - Scientific Discussion(0)
- EPAR - Scientific Discussion - Variation(0)
- EPAR - Steps taken after authorisation when a cutoff date has been used(0)
- Herbal - Call for data(0)
- Herbal - Herbal monograph(0)
- Herbal - HMPC assessment report(0)
- Herbal - HMPC opinion on a European Union herbal monograph(0)
- Herbal - List of references supporting the assessment report(0)
- Herbal - Overview of comments received during consultation(0)
- Herbal - Summary of assessment report for the public(0)
- Herbal – European Union herbal monograph(0)
- Herbal – European Union list entry(0)
- Leaflet(0)
- Maximum Residue Limits - Divergent opinion(0)
- Maximum Residue Limits - Opinion(0)
- Maximum Residue Limits - Report(0)
- Maximum Residue Limits - Summary of opinion(0)
- Medicine QA(0)
- Medicines under additional monitoring(0)
- Minutes(0)
- Newsletter(0)
- Opinion on any scientific matter(0)
- Opinion outside EU - All presentations(0)
- Opinion outside EU - Assessment report - Variation(0)
- Opinion outside EU - Medicine questions and answers(0)
- Opinion outside EU - Procedural steps taken and scientific information after opinion(0)
- Opinion outside EU - Procedural steps taken before opinion(0)
- Opinion outside EU - Product information(0)
- Opinion outside EU - Public assessment report(0)
- Opinion outside EU - Risk-management-plan summary(0)
- Opinion outside EU - Scientific discussion(0)
- Opinion outside EU - Summary for the public(0)
- Opinion outside EU - Summary of opinion(0)
- Opinion outside EU - Summary of opinion - Initial authorisation(0)
- Opinion outside EU - Withdrawal assessment report(0)
- Orphan designation(0)
- Orphan review(0)
- Other(0)
- Overview of comments(0)
- Parallel distribution(0)
- Periodic safety update single assessment(0)
- PIP - Notification of discontinuation of a paediatric development which is covered by an agreed PIP decision(0)
- PIP - Paediatric-investigation-plan summary(0)
- PIP decision(0)
- Position statement(0)
- PRAC recommendation on signal(0)
- Presentation(0)
- Press Release(0)
- Procurement(0)
- Public Statement(0)
- Recommendation on medication errors(0)
- Recruitment(0)
- Referrals document(0)
- Regulatory and procedural guideline(0)
- Report(0)
- Scientific guideline(0)
- Standard Operating Procedure - SOP(0)
- Summary of opinion(0)
- Summary of opinion - Initial authorisation(0)
- Supply shortage(0)
- Template or form(0)
- Withdrawal letter(0)
- Work Instruction - WIN(0)
- Work programme(0)
- Advanced therapies(400)
- Antimicrobial resistance(46)
- Biologicals(24)
- Biosimilars(157)
- Brexit(30)
- Careers(3)
- Clinical trials(190)
- Compassionate use(4)
- Compliance and inspections(106)
- Corporate(56)
- COVID-19(467)
- Data on medicines(174)
- Early access(25)
- Fees(13)
- Generic and hybrid medicines(402)
- Governance(95)
- Innovation(281)
- Maximum residue limit(17)
- Medication error(6)
- Medicines(7907)
- Medicines for use outside the EU(29)
- Medicine shortages(131)
- Mpox(18)
- Paediatrics(3134)
- Parallel distribution(6)
- Pharmacovigilance(2967)
- Procurement(10)
- Product information(63)
- Quality of medicines(87)
- Rare diseases(3316)
- Referrals(386)
- Regulatory and procedural guidance(557)
- Research and development(229)
- Scientific advice(38)
- Scientific guidelines(1019)
- SME(63)
- Vaccines(386)
- Veterinary limited markets(15)
Search results (24445)
dydrogesterone-estradiol
Procedure number:
PSUSA-00001276-202312
Regulatory outcome:
Variation
Last updated:
PSUSAHuman
risdiplam
Muscular Atrophy, Spinal
Date of authorisation:
Revision:
8
Last updated:
MedicineHumanAuthorised
doxazosin
Procedure number:
PSUSA/00001169/232312
Regulatory outcome:
Maintenance
Last updated:
PSUSAHuman
lopinavir
ritonavir
HIV Infections
Date of authorisation:
Revision:
19
Last updated:
MedicineHumanAuthorised
rivaroxaban
Arthroplasty, Replacement
Venous Thromboembolism
Date of authorisation:
Revision:
42
Last updated:
MedicineHumanAuthorised
entrectinib
Cancer
Carcinoma, Non-Small-Cell Lung
Date of authorisation:
Revision:
9
Last updated:
MedicineHumanAuthorised
Online
Start date:
11 September 2024, 10:00 (CEST)
End date:
11 September 2024, 13:30 (CEST)
EventHumanMedicine shortages
nilotinib
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Date of authorisation:
Last updated:
MedicineHumanAuthorised
ustekinumab
Psoriasis
Date of authorisation:
Last updated:
MedicineHumanAuthorised
fingolimod
Multiple Sclerosis, Relapsing-Remitting
Date of authorisation:
Revision:
8
Last updated:
MedicineHumanAuthorised